H.R. 1672

Summary

H.R. 1672, the Maintaining Investments in New Innovation Act, was introduced in the House on Feb 27, 2025 by Rep. Donald Davis (D) with 50 co-sponsors. It was referred to Energy And Commerce, and last saw action on Feb 27, 2025: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Record

Text

H.R. 1672 has 50 co-sponsors.

119 HR 1672 IH: Maintaining Investments in New Innovation Act
 U.S. House of Representatives
 2025-02-27
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
 I  119th CONGRESS  1st Session  H. R. 1672  IN THE HOUSE OF REPRESENTATIVES   February 27, 2025   Mr. Davis of North Carolina  (for himself,  Mr. Joyce of Pennsylvania ,  Mr. Gottheimer ,  Ms. Tenney ,  Mr. Yakym ,  Mr. Morelle ,  Mr. Hudson ,  Mr. Bean of Florida ,  Mrs. Miller-Meeks ,  Mr. Allen ,  Ms. Van Duyne ,  Mr. Peters ,  Mr. Moore of Utah , and  Mr. Crenshaw ) introduced the following bill; which was referred to the  Committee on Energy and Commerce , and in addition to the Committee on  Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned   A BILL
To amend title XI of the Social Security Act to protect access to genetically targeted technologies.
1.
Short title
This Act may be cited as the   Maintaining Investments in New Innovation Act  .
2.
Amendment to definition of qualifying single source drug
Section 1192(e) of the Social Security Act ( 42 U.S.C. 1320f–1(e) ) is amended—
(1)
in paragraph (1)(A)(ii), by inserting  (or, in the case of an advanced drug product (as defined in paragraph (4)), 11 years)  after  7 years ; and
(2)
by adding at the end the following new paragraph:
(4)
Advanced drug product defined
For purposes of paragraph (1)(A)(ii), the term  advanced drug product  means a drug that incorporates or utilizes a genetically targeted technology (as defined in section 529A(c)(2) of the Federal Food, Drug, and Cosmetic Act) that may result in the modulation (including suppression, up-regulation, or activation) of the function of a gene or its associated gene product.
 .

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

CRS Summary

The summaries are the Congressional Research Service’s, one per stage. Read them in full.

Sponsors

Rep. Donald Davis (D) sponsors H.R. 1672, and 50 members have co-sponsored it, 13 of them from the day it was introduced.

Donald Davis

Rep. · D–NC-1 · Sponsor

Introduced Feb 27, 2025

Rick Allen

Rep. · R–GA-12 · Co-sponsor

Joined Feb 27, 2025 · Original

Aaron Bean

Rep. · R–FL-4 · Co-sponsor

Joined Feb 27, 2025 · Original

Dan Crenshaw

Rep. · R–TX-2 · Co-sponsor

Joined Feb 27, 2025 · Original

Josh Gottheimer

Rep. · D–NJ-5 · Co-sponsor

Joined Feb 27, 2025 · Original

Richard Hudson

Rep. · R–NC-9 · Co-sponsor

Joined Feb 27, 2025 · Original

John Joyce

Rep. · R–PA-13 · Co-sponsor

Joined Feb 27, 2025 · Original

Mariannette Miller-Meeks

Rep. · R–IA-1 · Co-sponsor

Joined Feb 27, 2025 · Original

Blake Moore

Rep. · R–UT-1 · Co-sponsor

Joined Feb 27, 2025 · Original

Joseph Morelle

Rep. · D–NY-25 · Co-sponsor

Joined Feb 27, 2025 · Original

Show 10 of 51 rows

PreviousNext

Committees

H.R. 1672 went before 2 committees: Ways and Means and Energy and Commerce.

Ways and Means

Ways and Means

Referred To · Feb 27, 2025 · 1,160 Bills

Energy and Commerce

Energy and Commerce

Referred To · Feb 27, 2025 · 1,636 Bills

Actions

H.R. 1672 has taken 2 actions since Feb 27, 2025.

Votes

H.R. 1672 has not gone to a roll call.

Titles

H.R. 1672 goes by 3 titles, 1 of them short titles.

• Maintaining Investments in New Innovation Act — Display Title
• Maintaining Investments in New Innovation Act — Short Title(s) as Introduced
• To amend title XI of the Social Security Act to protect access to genetically targeted technologies. — Official Title as Introduced

Lobbying

23 clients hired 24 firms and 143 registered lobbyists who named H.R. 1672 in 155 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.

Filed under Health Issues, Medicare/Medicaid, Taxation/Internal Revenue Code, Trade (domestic/foreign), Budget/Appropriations, Copyright/Patent/Trademark, Pharmacy, Labor Issues/Antitrust/Workplace.

Clients

Who paid to be heard, by how many filings named the bill. The 20 that filed most often, of 23.

Firms

Registrants who filed on the bill, by filings.

Lobbyists

Named on the filings that cite the bill. The 20 named most often, of 143.

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.

Classification

The Congressional Research Service files H.R. 1672 under Health, one of its 31 policy areas, and gives it 3 legislative subjects.

CRS Subjects

CRS assigns every bill one policy area from its 31; H.R. 1672’s is Health.

Legislative Subjects

H.R. 1672 carries 3 of CRS’s legislative subjects, from Genetics to Prescription drugs.

Constitutional authority

The clause the sponsor cites as Congress’s power to enact H.R. 1672, as entered in the Congressional Record.

[Congressional Record Volume 171, Number 39 (Thursday, February 27, 2025)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mr. DAVIS of North Carolina:H.R. 1672.Congress has the power to enact this legislation pursuantto the following:Article I, Section 8, Clause 18.[Page H919]

Source: congress.gov · legiscan.com